液相芯片技术在非小细胞肺癌个体化化疗中应用-application of liquid chip technology in individualized chemotherapy of non-small cell lung cancer.docxVIP

下载本文档

13
0
约4.02万字
约 43页
2018-06-03 发布于上海
举报
版权申诉

液相芯片技术在非小细胞肺癌个体化化疗中应用-application of liquid chip technology in individualized chemotherapy of non-small cell lung cancer.docx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

液相芯片技术在非小细胞肺癌个体化化疗中应用-application of liquid chip technology in individualized chemotherapy of non-small cell lung cancer

Application of suspension array technology in Individual chemotherapy for non-small cell lung cancerStudent:Liu Yuan-yuan Supervisor:Pro.Wang Yuan-dongABSTRACTBackground:Primary bronchial lung cancer, abbreviated as lung cancer, is a kind of malignant tumor deriving from bronchial mucous membrane or gland . It is one of the most common malignant tumour in the world. accounts for 16% of all malignant tumour, 28 percent of all cancer deaths. its morbidity has had the tendency to rise obviously in the past 50 years. In the past 10 years, the global incidence rate of lung cancer increases at the speed of 22% every year, there are 1.2 million new cases and 1.1 million deathseach year. In the worldwide, both men and women, lung cancer has become the leading cause of cancer deaths. The incidence rate of lung cancer in China takes the first place of malignant tumour in the city at present, occupies the 3rd place in the rural areas. Since 1996, lung cancer of our country had already occupied the first place in the cause of the cancer deaths. Non-small cell lung cancer is the main pathological types of lung cancer, accounting for 80 percent. lung cancer in early stage has no obvious or only mild symptoms.When the patients go toa doctor after having obviously clinical symptoms, they have mostly already belonged to the later period so that clinical treatment and the median survival period are unsatisfactory. At present, the clinical diagnosis of lung cancer rely ma inly on imaging, Cytopathology and the organization,etc.However,these traditional methods lack sufficient sensitivity and specificity.70% of the NSCLC is already in advanced when found, which losesn the opportunity to surgery and multi-disciplinary complex treatment. chemotherapy as an important component of the comprehensive treatment, is the primarymeans of treatment. However, due to heterogeneity among individual presence, patients with the same pathological type and stage of NSCLC have great diffe